Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/104480
Full metadata record
DC FieldValueLanguage
dc.contributor.CRUESPUNIVERSIDADE DE ESTADUAL DE CAMPINASpt_BR
dc.typeEditorialpt_BR
dc.titleProphylactic Hpv Vaccines [vacinas Profiláticas Para O Hpv]pt_BR
dc.contributor.authorDerchain S.F.M.pt_BR
dc.contributor.authorSarian L.O.Z.pt_BR
unicamp.authorDerchain, S.F.M., Departamento de Tocoginecologia, Faculdade de Ciências Médicas, Universidade Estadual de Campinas - UNICAMP, Campinas (SP), Brazil, Cidade Universitária, Rua Dr. António Hossri, 629, CEP 13083-370 - Campinas/SP, Brazilpt_BR
unicamp.authorSarian, L.O.Z., Departamento de Tocoginecologia, Faculdade de Ciências Médicas, Universidade Estadual de Campinas - UNICAMP, Campinas (SP), Brazilpt_BR
dc.description.abstract[No abstract available]en
dc.relation.ispartofRevista Brasileira de Ginecologia e Obstetriciapt_BR
dc.date.issued2007pt_BR
dc.identifier.citationRevista Brasileira De Ginecologia E Obstetricia. , v. 29, n. 6, p. 281 - 284, 2007.pt_BR
dc.language.isoptpt_BR
dc.description.volume29pt_BR
dc.description.issuenumber6pt_BR
dc.description.firstpage281pt_BR
dc.description.lastpage284pt_BR
dc.rightsabertopt_BR
dc.sourceScopuspt_BR
dc.identifier.issn1007203pt_BR
dc.identifier.doi10.1590/S0100-72032007000600001pt_BR
dc.identifier.urlhttp://www.scopus.com/inward/record.url?eid=2-s2.0-37349037558&partnerID=40&md5=5acd086cb29601dcc87df86de190125cpt_BR
dc.date.available2015-06-30T18:43:03Z
dc.date.available2015-11-26T14:32:34Z-
dc.date.accessioned2015-06-30T18:43:03Z
dc.date.accessioned2015-11-26T14:32:34Z-
dc.description.provenanceMade available in DSpace on 2015-06-30T18:43:03Z (GMT). No. of bitstreams: 1 2-s2.0-37349037558.pdf: 99165 bytes, checksum: d959fdd6760806f73509b021ada29791 (MD5) Previous issue date: 2007en
dc.description.provenanceMade available in DSpace on 2015-11-26T14:32:34Z (GMT). No. of bitstreams: 2 2-s2.0-37349037558.pdf: 99165 bytes, checksum: d959fdd6760806f73509b021ada29791 (MD5) 2-s2.0-37349037558.pdf.txt: 22453 bytes, checksum: 8b49afee7ebaeb7c418fc52902e2b106 (MD5) Previous issue date: 2007en
dc.identifier.urihttp://www.repositorio.unicamp.br/handle/REPOSIP/104480
dc.identifier.urihttp://repositorio.unicamp.br/jspui/handle/REPOSIP/104480-
dc.identifier.idScopus2-s2.0-37349037558pt_BR
dc.description.referenceMunoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006;24 Suppl 3:S1-S10Lazcano-Ponce, E., Alonso, P., Ruiz-Moreno, J.A., Hernandez-Avila, M., Recommendations for cervical cancer screening programs in developing countries. The need for equity and technological development (2003) Salud Publica Mex, 45 (SUPPL. 3), pp. S449-S462pt_BR
dc.description.referenceLowy, D.R., Schiller, J.T., Prophylactic human papillomavirus vaccines (2006) J Clin Invest, 116 (5), pp. 1167-1173pt_BR
dc.description.referenceTewari, K.S., DiSaia, P.J., Primary prevention of uterine cervix cancer: Focus on vaccine history and current strategy (2002) Obstet Gynecol Clin North Am, 29 (4), pp. 843-868pt_BR
dc.description.referenceVilla LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6(5):271-8Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine. 2006;24(27-28):5571-83Harro, C.D., Pang, Y.Y., Roden, R.B., Hildesheim, A., Wang, Z., Reynolds, M.J., Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine (2001) J Natl Cancer Inst, 93 (4), pp. 284-292pt_BR
dc.description.referenceKoutsky, L.A., Ault, K.A., Wheeler, C.M., Brown, D.R., Barr, E., Alvarez, F.B., A controlled trial of a human papillomavirus type 16 vaccine (2002) N Engl J Med, 347 (21), pp. 1645-1651pt_BR
dc.description.referenceHarper, D.M., Franco, E.L., Wheeler, C., Ferris, D.G., Jenkins, D., Schuind, A., Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial (2004) Lancet, 364 (9447), pp. 1757-1765pt_BR
dc.description.referenceHarper, D.M., Franco, E.L., Wheeler, C.M., Moscicki, A.B., Romanowski, B., Roteli-Martins, C.M., Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial (2006) Lancet, 367 (9518), pp. 1247-1255pt_BR
dc.description.referenceJoura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007;369(9574):1693-702Ault, K.A., Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: A combined analysis of four randomised clinical trials (2007) Lancet, 369 (9576), pp. 1861-1868pt_BR
dc.description.referenceSchiller JT, Nardelli-Haefliger D. Chapter 17: second generation HPV vaccines to prevent cervical cancer. Vaccine. 2006;24 Suppl 3:S147-53Franco EL, Cuzick J, Hildesheim A, de Sanjose S. Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine. 2006;24 Suppl 3:S171-7Zimmerman, R.K., Ethical analysis of HPV vaccine policy options (2006) Vaccine, 24 (22), pp. 4812-4820pt_BR
dc.description.referenceGoldie SJ, Kim JJ, Myers E. Chapter 19: cost-effectiveness of cervical cancer screening. Vaccine. 2006;24 Suppl 3:S164-70Goldie, S.J., Grima, D., Kohli, M., Wright, T.C., Weinstein, M., Franco, E., A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine (2003) Int J Cancer, 106 (6), pp. 896-904pt_BR
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
2-s2.0-37349037558.pdf96.84 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.